This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
What to Expect from Epizyme (EPZM) This Earnings Season?
by Zacks Equity Research
Epizyme, Inc. (EPZM) is scheduled to report first-quarter 2017 results on May 8, before the opening bell.
Exelixis (EXEL) Posts Earnings in Q1, Cabometyx in Focus
by Zacks Equity Research
Exelixis posted earnings in the first quarter of 2017 while revenues beat estimates driven by Cabometyx.
What to Expect from Prothena (PRTA) This Earnings Season?
by Zacks Equity Research
Prothena Corporation plc (PRTA) is expected to report first-quarter 2017 results early next month.
Novartis Tops Q1 Earnings: Cosentyx, Entresto Boost Sales
by Zacks Equity Research
Novartis AG (NVS) reported first-quarter 2017 core earnings of $1.13 per share, beating the Zacks Consensus Estimate of $1.10.
Pharma Stock Roundup: J&J Slips on Mixed Q1, Lilly Hit by FDA CRL
by Arpita Dutt
Key highlights from the pharma sector include J&J's (JNJ) first quarter results and a CRL for Lilly's RA drug.
After Johnson & Johnson Earnings, Buy These Pharma Stocks
by Ryan McQueeney
Shares of Johnson & Johnson (JNJ) slid nearly 3.5% in morning trading Tuesday after the pharma giant's first-quarter earnings results were met with mixed reactions from investors. As the sell-off continues, investors focused on large-cap pharma companies may want to move their money into stronger options this earnings season.
Roche's (RHHBY) Cancer Drug Gets FDA Nod for Label Expansion
by Zacks Equity Research
Roche Holding AG's (RHHBY) unit, Genentech, announced that its drug Tecentriq (atezolizumab) has received FDA approval on an accelerated basis for initial treatment of people with advanced urothelial carcinoma (mUC).
Roche's Hemophilia A Drug Positive in Second Phase III Study
by Zacks Equity Research
Roche Holding AG's (RHHBY) unit, Genentech, announced positive interim results from the Phase III HAVEN 2 study evaluating its pipeline candidate emicizumab prophylaxis.
Roche Launches Antibody Test to Diagnose Prostate Cancer
by Zacks Equity Research
Roche Holding AG (RHHBY) announced that it has launched the anti-p504s (SP116) Rabbit Monoclonal Primary Antibody for prostate cancer diagnosis on a world wise basis.
Pharma Stock Roundup: Merck Gets CRL for Label Expansion Effort, Roche Cancer Drug Tops
by Arpita Dutt
Key highlights this week include a complete response letter (CRL) for Merck (MRK) and some positive data from Roche.
Geron Stock Rises after Positive Interim Update on Imetelstat
by Zacks Equity Research
Shares of Geron Corporation (GERN) increased almost 20% on Monday after it provided a positive update on two late-stage studies for imetelstat, its lead pipeline candidate.
Louisiana-Pacific, Bed Bath & Beyond, Roche Holdings AG, Adidas AG and Deere highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Louisiana-Pacific, Bed Bath & Beyond, Roche Holdings AG, Adidas AG and Deere highlighted as Zacks Bull and Bear of the Day
Forget Novartis, Buy These Two Pharma Stocks Instead
by Arpita Dutt
With Novartis (NVS) being a Zacks Rank #4 (Sell) stock, here is a look at two European pharma stocks that sport a strong Zacks Rank.
Roche's Lung Cancer Drug Alecensa Meets Primary Endpoint
by Zacks Equity Research
Roche (RHHBY) announced that the global, randomized phase III study, ALEX, on lung cancer drug Alecensa met its primary endpoint as an initial (first-line) treatment.
Huh? Brazil Matters? Global Week Ahead
by John Blank
Peaking at +10.7% y/y in January 2016, Brazilian inflation now runs under +5% y/y. Risk markets in Brazil have also sharply pared down forward inflation expectations.
Allergan (AGN) Presents Mixed Depression Data on Botox
by Zacks Equity Research
Allergan plc (AGN) announced mixed top-line data from a mid-stage study evaluating its key drug Botox for the treatment of major depressive disorder (MDD).
Roche Announces Positive Data on Lung Cancer Drug Alecensa
by Zacks Equity Research
Roche Holdings AG (RHHBY) recently announced encouraging results from the phase III study, ALUR on lung cancer drug Alecensa.
AbbVie/J&J's Imbruvica Label Expansion Filing Accepted by FDA
by Zacks Equity Research
AbbVie Inc. (ABBV) and partner Janssen, Johnson & Johnson's (JNJ) pharmaceuticals subsidiary, announced that a supplemental new drug application (sNDA) for their cancer drug Imbruvica has been accepted for review by the FDA.
Bristol-Myers Announces Data on Immuno-oncology Drug Opdivo
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) recently announced encouraging data from various trials on Opdivo.
Sanofi's (SNY) Diabetes Drug Toujeo Lowers Hypoglycemia Risk
by Zacks Equity Research
A real-world observational study showed that when type 2 diabetes patients on basal insulin switched to Toujeo, it led to a significant reduction in risk of hypoglycemia without compromising blood sugar control
Bristol-Myers (BMY), Incyte to Advance Clinical Program
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) and Incyte Corporation (INCY) recently announced that the companies will advance their clinical development program.
AstraZeneca's (AZN) Lung Cancer Drug Gets Full FDA Approval
by Zacks Equity Research
AstraZeneca plc (AZN) announced that its lung cancer drug, Tagrisso has received full approval from the FDA.
Pfizer Gets Regular Approval for Breast Cancer Drug Ibrance
by Zacks Equity Research
Pfizer, Inc. (PFE) announced that its supplemental new drug application (sNDA) to convert accelerated approval for Ibrance to regular approval has been approved by the FDA.
4 FDA Decisions to Watch Out for in Apr 2017
by Arpita Dutt
Companies like BioMarin (BMRN), Roche and Takeda among others have regulatory decisions scheduled for this month.
Mylan Receives CRL for Generic Advair Diskus From the FDA
by Zacks Equity Research
Mylan N.V. (MYL) recently suffered a huge setback when it received a complete response letter from the FDA regarding its ANDA for the generic version of asthma drug Advair Diskus.